2月5日 - ** 在雷特治疗药物申请遭遇欧洲监管机构挫折后，杰富瑞下调了Neuren PharmaceuticalsNEU.AX的目标价和年度盈利预测
** NEU 周二称， (link) 许可证持有者Acadia Pharmaceuticals
** 杰富瑞（Jefferies）表示，由于最近的挫折，它现在假定欧盟的特罗非肽专利权使用费将从第四季度开始，而不是第二季度，因此将NEU26财年的净利润预测从5,820万澳元下调至4,810万澳元(3,348万美元)
** 将目标股价从 27.75 澳元下调至 27 澳元，维持 "买入 "评级
** 截至上次收盘，股价年累计下跌 29.1%
(1 美元 = 1.4366 澳元)
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.